Revance Reports Second Quarter 2021 Financial Results, Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Revance Therapeutics (RVNC) Misses Q2 EPS by 2c
August 5, 2021 4:51 PM EDTRevance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($1.07), $0.02 worse than the analyst estimate of ($1.05). Revenue for the quarter came in at $18 million versus the consensus estimate of $15.48 million.
Cash, cash equivalents and short-term investments as of June 30, 2021 were $336.3 million.
For earnings history and... More
